t
On 17 January 2024, Futura Medical plc reported that Director James Barder and his spouse, Charlotte Barder, gifted an aggregate of 20,000 Ordinary Shares to a family member at nil consideration, as part of inheritance and tax planning. Following this transaction, James Barder's interest in Ordinary Shares is 1,420,972, representing approximately 0.5% of the Company's issued share capital.
| Date | 17 Jan 2024 |
| Time | 07:00:06 |
| Category | Director/PDMR dealings |
| ID | 8963Z |
17 January 2024
Futura Medical plc
("Futura" or the "Company")
Director/PDMR Dealing
Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, today announces that it has been notified that James Barder and his spouse, Charlotte Barder have gifted in aggregate 20,000 Ordinary Shares to a family member as part of inheritance and tax planning.
Following this transaction James Barder's interests in Ordinary Shares is 1,420,972 Ordinary Shares, representing approximately 0.5% of the Company's issued share capital.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: [email protected]
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin / Jonathan Edwards / Elena Bates
Email: [email protected]
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing innovative products based on its proprietary, transdermal DermaSys® technology.
MED3000, the Company's breakthrough treatment for erectile dysfunction ("ED") has a unique evaporative mode of action and is clinically proven as an effective topical treatment for adult men with ED, with a key claim of "Helps you get an erection within 10 minutes". Eroxon® is available Over the Counter ("OTC") without a doctor's prescription. www.eroxon.com.
MED3000 is being manufactured and commercialised under the brand name Eroxon® and has been granted marketing authorisation by the FDA in the US, CE marked in Europe, UKCA marked in the UK and is gaining regulatory approval in a growing number of countries across the world. Futura has commercial agreements with Haleon for the US market and Cooper Consumer Health for Europe.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com.
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||||||||
|
a)
|
Name |
James Barder |
|||||||||
|
2 |
Reason for the notification |
||||||||||
|
a)
|
Position/status
|
Director/ PDMR |
|||||||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||||||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||
|
a)
|
Name
|
Futura Medical plc |
|||||||||
|
b)
|
LEI
|
21380053QLT46UNV2303 |
|||||||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of 0.2p each
GB0033278473 |
|||||||||
|
b)
|
Nature of the transaction
|
1. Transfer to PCA 2. Transfer to family member |
|||||||||
|
c)
|
Price(s) and volume(s)
|
|
|||||||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable
|
|||||||||
|
e)
|
Date of the transaction
|
17 January 2024 |
|||||||||
|
f)
|
Place of the transaction
|
Outside of trading venue |
|||||||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||||||||
|
a)
|
Name |
Charlotte Barder |
|||||||||
|
2 |
Reason for the notification |
||||||||||
|
a)
|
Position/status
|
PCA of James Barder |
|||||||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||||||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||
|
a)
|
Name
|
Futura Medical plc |
|||||||||
|
b)
|
LEI
|
21380053QLT46UNV2303 |
|||||||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of 0.2p each
GB0033278473 |
|||||||||
|
b)
|
Nature of the transaction
|
1. Receipt of shares from PCA 2. Transfer to family member |
|||||||||
|
c)
|
Price(s) and volume(s)
|
|
|||||||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable
|
|||||||||
|
e)
|
Date of the transaction
|
17 January 2024 |
|||||||||
|
f)
|
Place of the transaction
|
Outside of trading venue |
|||||||||